Author of

• 18374

  +

  P3.02b - Poster Session with Presenters Present (ID 494)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 18468

    +

    P3.02b-094 - Rebiopsy Post Progression in EGFR Mutated Lung Cancer (ID 5989)

    14:30 - 14:30  |  Author(s): V. Norohna
    • Abstract
    • Slides

    Background:
    Post progression on treatment with chemotherapy/TKIs , adenocarcinoma of the lung may transform histologically or gain /lose receptor function
    
    Methods:
    This was a post hoc analysis of a phase 3 randomized study. Classic activating EGFR mutation positive patients warranting palliative chemotherapy were enrolled in this study and randomized to either gefitinib or pemetrexed carboplatin doublet. The data regarding rebiopsy post progression on first line was collected for this analysis and descriptive analysis was performed
    
    Results:
    We had 290 patients out of which 214 patients had progressed. The initial EGFR mutation status of these patients was exon 21 in 85 patients (39.7%),exon 19 in 124 patients (57.9%) and exon 18 in 5 patients (2.4%). The 4 most common reasons for not doing the biopsy following progression were ; biopsy not offered in 57 patients , no measurable or biopsiable lesion in 13 patients, poor PS in 13 patients and measurable lesion in the sanctuary site (brain) in 12 patients. 92 (43%) patients underwent rebiopsy at first progression. The site of biopsy were lung in 83 (90.2%) patients, extrathoracic metastatic sites in 6 (6.5%) patients and lymph nodes in 3 (3.3%) patients. Adequate tissue for histopathological examination were available in 84 patients (91.3%). In 8 patients (8.7%) representative tissue could not be obtained. The histopathology was adenocarcinoma in 81 (96.4%, n=84 ) patients and it was SCLC, squamous cell carcinoma and poorly differentiated carcinoma in one patient each (1.2%). The molecular analysis for EGFR mutation status will be presented at the conference
    
    Conclusion:
    Nearly half of the patients underwent repeat biopsies in this prospective setting. The commonest reason for non biopsy was physician reluctance and histopathological transformation to SCLC was seen in 1.2% of patients
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.